Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 11/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | PYGL | P06737 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19962078 | 1.00 | OXTR (0.41) | OXTRAVPR1ASCN9APYGLROCK2 | |
| SCHEMBL19962092 | 0.93 | OXTR (0.36) | OXTRAVPR1ASCN9APYGLROCK2 | |
| SCHEMBL19962022 | 0.89 | PYGL (0.37) | OXTRSCN9APYGL | |
| SCHEMBL19969320 | 0.89 | PYGL (0.37) | OXTRSCN9APYGL | |
| SCHEMBL18180125 | 0.88 | PYGL (0.40) | PYGLMEN1KMT2ALMNA | |
| SCHEMBL19969153 | 0.86 | PYGL (0.36) | PYGLROCK2ROCK1KMT2A | |
| SCHEMBL19962159 | 0.86 | PYGL (0.36) | PYGLROCK2ROCK1KMT2A | |
| SCHEMBL19962153 | 0.85 | ROCK2 (0.35) | SCN9APYGLROCK2ROCK1MEN1 | |
| SCHEMBL19969470 | 0.85 | ROCK2 (0.35) | SCN9APYGLROCK2ROCK1MEN1 | |
| SCHEMBL19969222 | 0.85 | PYGL (0.37) | SCN9APYGLROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | OXTR 4775/4885AVPR1A 3448/4885SCN9A 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.